AeroVanc ( DrugBank: - )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
299嚢胞性線維症4

299. 嚢胞性線維症


臨床試験数 : 1,696 薬物数 : 1,644 - (DrugBank : 272) / 標的遺伝子数 : 96 - 標的パスウェイ数 : 170
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03181932
(ClinicalTrials.gov)
September 20, 20171/6/2017AeroVanc in the Treatment of Methicillin-resistant Staphylococcus Aureus Infection in Patients With Cystic FibrosisA Phase III, Randomized, Double-blind, Placebo-controlled Study of AeroVanc for the Treatment of Persistent Methicillin-resistant Staphylococcus Aureus Lung Infection in Cystic Fibrosis PatientsMRSA;Cystic FibrosisDrug: Vancomycin inhalation powder;Drug: Placebo inhalation powderSavara Inc.NULLCompleted6 YearsN/AAll188Phase 3United States;Canada
2NCT01746095
(ClinicalTrials.gov)
March 20136/12/2012Efficacy and Safety Study of AeroVanc for the Treatment of Persistent MRSA Lung Infection in Cystic Fibrosis PatientsA Phase 2, Randomized, Double Blind, Placebo-controlled Study of AeroVanc for the Treatment of Persistent Methicillin-resistant Staphylococcus Aureus Lung Infection in Cystic Fibrosis PatientsCystic FibrosisDrug: Vancomycin hydrochloride inhalation powder;Drug: Placebo inhalation powderSavara Inc.Synteract, Inc.;Cystic Fibrosis FoundationCompleted12 YearsN/AAll87Phase 2United States
3NCT01537666
(ClinicalTrials.gov)
November 201117/2/2012Inhaled Vancomycin Tolerability, Safety and PharmacokineticsPhase I, Reference-controlled, Dose Escalating Study to Examine the Pharmacokinetics and Safety of AeroVanc Inhalation Powder.Healthy;Cystic FibrosisDrug: AeroVanc;Drug: IV vancomycin hydrochlorideSavara Inc.INC Research LimitedCompleted18 Years50 YearsAll25Phase 1Australia
4EUCTR2005-000313-35-GB
(EUCTR)
13/04/200517/03/2005A Phase I/II Study to Investigate the Efficacy and Safety of AER 002 in Cystic Fibrosis Given at 3 mg, 10 mg, and 30 mg Doses in Single then Multiple Ascending Doses and to Determine Efficacy of the Highest Tolerable Dose in a 4-Week Proof of Concept StudyA Phase I/II Study to Investigate the Efficacy and Safety of AER 002 in Cystic Fibrosis Given at 3 mg, 10 mg, and 30 mg Doses in Single then Multiple Ascending Doses and to Determine Efficacy of the Highest Tolerable Dose in a 4-Week Proof of Concept Study Cystic Fibrosis
MedDRA version: 7.1;Level: LLT;Classification code 10011762
Product Name: Recombinant truncated SPINT2 protease inhibitor
Product Code: AER002
Aerovance IncNULLNot RecruitingFemale: yes
Male: yes
106Phase 1;Phase 2United Kingdom